A Novel Combined Nanoparticle Delivery of Poly(ADP-Ribose) Polymerase Inhibitor-Olaparib and Copper Complexes for Chemosensitization Therapy in Breast Cancer

doi:10.21127/yaoyimr20230007

Medicine Research ›› 2023, Vol. 7 ›› Issue (3-4): 230007-230007.DOI: 10.21127/yaoyimr20230007

• Reports • Previous Articles Next Articles

A Novel Combined Nanoparticle Delivery of Poly(ADP-Ribose) Polymerase Inhibitor-Olaparib and Copper Complexes for Chemosensitization Therapy in Breast Cancer

Xiaoya Huang, Kehai Liu^*

Department of Biopharmaceutical Sciences, Shanghai Ocean University, Shanghai 201306, China

Received:2023-09-22 Revised:2023-10-20 Accepted:2023-10-30 Online:2023-12-20 Published:2024-02-22
Contact: * Email: khliu@shou.edu.cn (K. L.)

Abstract

Abstract: Chemo-sensitization therapy has gained importance in the field of anti-cancer treatment in recent years. The combination of both chemotherapy and chemosensitization has unique advantages. However, there has been relatively limited research on combination treatment using metal complexes and chemosensitizers. Herein, we reports a two-drug synergistic delivery system combining a copper complex and a chemosensitizer Olaparib in a certain ratio of safety and efficiency is the key. Polyethylenimine (PEI) was chemically-linked to activated chemosensitizer Olaparib, which was connected to a bifunctional peptide, T15, for facilitation and nuclear targeting, resulting in Ola-PEI-T15. Then, a novel metal complex Cu/Ola-PEI-T15 was obtained by Cu²⁺ coordination to Ola-PEI-T15. The two therapeutic agents can be transported into the cells at the same time, giving full play to the synergistic anti-tumor effect.

Key words: chemosensitization, olaparib, metal complex, synergistic anti-tumor effect

Xiaoya Huang, Kehai Liu. A Novel Combined Nanoparticle Delivery of Poly(ADP-Ribose) Polymerase Inhibitor-Olaparib and Copper Complexes for Chemosensitization Therapy in Breast Cancer[J]. Medicine Research, 2023, 7(3-4): 230007-230007.

References

[1] Baldwin P.; Ohman A. W.; Tangutoori S.; Dinulescu D. M.; Sridhar S.; Baldwin P.; Ohman A. W.; Tangutoori S.; Dinulescu D. M.; Sridhar S.Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int. [J]. Nanomed. 2018, 13, 8063-8074.
[2] Belz J. E.; Kumar R.; Baldwin P.; Ojo N. C.; Leal A. S.; Royce D. B.; Zhang D.; van de Ven, A. L.; Liby, K. T.; Sridhar, S.; Belz, J. E.; Kumar, R.; Baldwin, P.; Ojo, N. C.; Leal, A. S.; Royce, D. B.; Zhang, D.; van de Ven, A. L.; Liby, K. T.; Sridhar, S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics 2017, 7, 4340-4349.
[3] Chen L. M.; Yang P. P.; Al Haq, A. T.; Hwang, P. A.; Lai, Y. C.; Weng, Y. S.; Chen, M. A.; Hsu, H. L.; Chen, L. M.; Yang, P. P.; Al Haq, A. T.; Hwang, P. A.; Lai, Y. C.; Weng, Y. S.; Chen, M. A.; Hsu, H. L. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. [J]. Biomed. Sci. 2022, 29, 70.
[4] Du C.; Qi Y.; Zhang Y.; Wang Y.; Zhao X.; Min H.; Han X.; Lang J.; Qin H.; Shi Q.; Zhang Z.; Tian X.; Anderson G. J.; Zhao Y.; Nie G.; Yang Y.; Du C.; Qi Y.; Zhang Y.; Wang Y.; Zhao X.; Min H.; Han X.; Lang J.; Qin H.; Shi Q.; Zhang Z.; Tian X.; Anderson G. J.; Zhao Y.; Nie G.; Yang Y.Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. ACS Nano 2018, 12, 10785-10796.
[5] Wang Y.; Zheng K.; Huang Y.; Xiong H.; Su J.; Chen R.; Zou Y.; Wang Y.; Zheng K.; Huang Y.; Xiong H.; Su J.; Chen R.; Zou Y.PARP inhibitors in gastric cancer: beacon of hope. [J]. Exp. Clin. Cancer Res. 2021, 40, 211.
[6] Wu M.; Liu J.; Hu C.; Li D.; Yang J.; Wu Z.; Yang L.; Chen Y.; Fu S.; Wu J.; Wu M.; Liu J.; Hu C.; Li D.; Yang J.; Wu Z.; Yang L.; Chen Y.; Fu S.; Wu J.Olaparib nanoparticles potentiated radiosensitization effects on lung cancer. Int. [J]. Nanomed. 2018, 13, 8461-8472.
[7] Xie H.; Wang W.; Xia B.; Jin W.; Lou G.; Xie H.; Wang W.; Xia B.; Jin W.; Lou G.Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed. Pharmacother. 2020, 127, 110204.
[8] Yuan Z.; Chen J.; Li W.; Li D.; Chen C.; Gao C.; Jiang Y.PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert. Opin. Ther. Pat. 2017, 27, 363-382.
[9] Zhang D.; Baldwin P.; Leal A. S.; Carapellucci S.; Sridhar S.; Liby K. T.; Zhang D.; Baldwin P.; Leal A. S.; Carapellucci S.; Sridhar S.; Liby K. T.A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics 2019, 9, 6224-6238.
[10] Pathade A. D.; Kommineni N.; Bulbake U.; Thummar M. M.; Samanthula G.; Khan W.; Pathade A. D.; Kommineni N.; Bulbake U.; Thummar M. M.; Samanthula G.; Khan W.Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib AAPS. PharmSciTech 2019, 20, 276.
[11] Erol K.; Kose K.; Uzun L.; Say R.; Denizli A.; Erol K.; Kose K.; Uzun L.; Say R.; Denizli A.Polyethyleneimine assisted-two-step polymerization to develop surface imprinted cryogels for lysozyme purification. Colloids Surf. B Biointerfaces 2016, 146, 567-576.
[12] Fu Z.; Mao Y.; Li S.; Liu S.; Shao C.; Shang P.; Li Q.; Wu C.; Fu Z.; Mao Y.; Li S.; Liu S.; Shao C.; Shang P.; Li Q.; Wu C.Preparation and characterization of ABS and copper (II) sulfate coordination composites by planetary ball mill. Polym. Bulletin 2017, 75, 453-468.
[13] Hassan I.; Ebaid H.; Alhazza I. M.; Al-Tamimi, J.; Aman, S.; Abdel-Mageed, A. M.; Hassan, I.; Ebaid, H.; Alhazza, I. M.; Al-Tamimi, J.; Aman, S.; Abdel-Mageed, A. M. Copper Mediates Anti-Inflammatory and Antifibrotic Activity of Gleevec in Hepatocellular Carcinoma-Induced Male Rats. Can. [J]. Gastroenterol. Hepatol. 2019, 2019, 9897315.
[14] Sargazi S.; Mukhtar M.; Rahdar A.; Barani M.; Pandey S.;Diez-Pascual, A. M.; Sargazi, S.; Mukhtar, M.; Rahdar, A.; Barani, M.; Pandey, S.; Diez-Pascual, A. M. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. Int. J. Mol. Sci. 2021, 22, 10319.
[15] Gong C.; Yu X.; You B.; Wu Y.; Wang R.; Han L.; Wang Y.; Gao S.; Yuan Y.; Gong C.; Yu X.; You B.; Wu Y.; Wang R.; Han L.; Wang Y.; Gao S.; Yuan Y.Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. [J]. Nanobiotechnol. 2020, 18, 92.

A Novel Combined Nanoparticle Delivery of Poly(ADP-Ribose) Polymerase Inhibitor-Olaparib and Copper Complexes for Chemosensitization Therapy in Breast Cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics